Shop By
Catalog No.
Product Name
Application
Product Information
Citations
-
HMGB1 release inhibitor
Ethyl pyruvate is a simple derivative of the endogenous metabolite, pyruvic acid. Ethyl pyruvate is an anti-inflammatory agent. -
inhibitor of tubulin polymerization
4-Oxo-4-HPR is an inhibitor of tubulin polymerization, inducing marked G2-M cell cycle arrest and apoptosis in fenretinide-sensitive and fenretinide-resistant cell lines. It is also a fenretinide metabolite. -
Rac1/Cdc42 Inhibitor
AZA1 is a potent dual inhibitor of Rac1 and Cdc42, key regulators of cell signaling pathways. This compound has been shown to induce apoptosis in prostate cancer cells while simultaneously inhibiting their proliferation, migration, and invasion. AZA1 serves as a valuable tool for research into the molecular mechanisms of prostate cancer progression and potential therapeutic interventions. -
Tyrosinase Inhibitor
Norartocarpetin is a potent tyrosinase inhibitor, demonstrating significant inhibition with an IC50 value of 0.47 μM. This compound serves as an effective antibrowning agent for food systems research and exhibits notable anticancer activity against lung carcinoma cells (NCI-H460) with an IC50 of 22 μM. Its antiproliferative effects are mediated through targeting the Ras/Raf/MAPK signaling pathway, inducing mitochondrial-mediated apoptosis, causing S-phase cell cycle arrest, and inhibiting cell migration and invasion in human lung carcinoma cells. -
HDAC Inhibitor
HC-Toxin is a potent histone deacetylase (HDAC) inhibitor with an IC50 of 30 nM. This cyclic tetrapeptide effectively induces apoptosis in tumor cells, demonstrating significant anticancer activity. Its mechanism of action makes it valuable for research in cancer therapy and the modulation of gene expression. -
Cdc42 GTPase Inhibitor
ML141 (CID-2950007) is a potent, allosteric, selective and reversible non-competitive inhibitor of Cdc42 GTPase. ML141 inhibits Cdc42 wild type and Cdc42 Q61L mutant with EC50s of 2.1 and 2.6 μM, respectively. ML141 shows low micromolar potency and selectivity against other members of the Rho family of GTPases (Rac1, Rab2, Rab7). ML141 do not show cytotoxicity in multiple cell lines. -
Topoisomerase IV Inhibitor
Ciprofloxacin is a potent topoisomerase IV inhibitor that demonstrates significant antibacterial activity as a fluoroquinolone antibiotic. It induces both mitochondrial and nuclear DNA damage, leading to mitochondrial dysfunction and increased reactive oxygen species (ROS) production. Ciprofloxacin exhibits anti-proliferative properties and triggers apoptotic pathways, making it a valuable tool for research applications focused on bacterial infections, oxidative stress, and cancer biology. -
Tubulin Inhibitor
Demecolcine is a potent tubulin inhibitor that effectively disrupts microtubule polymerization, exhibiting an IC50 value of 2.4 μM. By binding to tubulin dimers, Demecolcine exerts anti-mitotic effects, hindering cellular division. This compound is primarily utilized in research related to inflammatory disorders and various cancer pathways, making it valuable for studies focused on cell cycle regulation and targeted therapies. -
TNF Receptor Inhibitor
Muscone, a TNF receptor inhibitor, is derived from the traditional Chinese medicine musk. It effectively inhibits NF-κB signaling and NLRP3 inflammasome activation, resulting in a significant reduction of inflammatory cytokines such as IL-1β, TNF-α, and IL-6. This compound is valuable in research focused on inflammation, cardiac function restoration, and improving survival rates in various pathological conditions. -
Bcl-xL/Bcl-2 Inhibitor
BM-1244 is a selective inhibitor of Bcl-xL and Bcl-2, exhibiting Ki values of 134 nM and 450 nM, respectively. This compound induces apoptosis and suppresses tumor growth through the release of cytochrome C and Smac from mitochondria, leading to caspase-3 activation and PARP cleavage. BM-1244 has demonstrated synergistic effects with chemotherapy in vivo, making it a valuable research tool for studying colorectal cancer, acute myeloid leukemia, and gastric cancer. -
Bcl-2/Bcl-xl Inhibitor
Pelcitoclax is a potent inhibitor of Bcl-2 and Bcl-xl, designed to induce apoptosis in cancer cells. Its primary mechanism involves disrupting the anti-apoptotic activity of these proteins, leading to increased cell death in malignant tissues. Pelcitoclax is utilized in research to explore therapeutic strategies against various malignancies and to study apoptotic pathways in cellular models. -
Bcl-2/Bcl-xl Inhibitor
Lisaftoclax is a potent inhibitor of the anti-apoptotic proteins Bcl-2 and Bcl-xl. With IC50 values of 2 nM for Bcl-2 and 5.9 nM for Bcl-xl, Lisaftoclax demonstrates significant anti-tumor activity. This compound is primarily utilized in research focused on cancer therapy, particularly in studies exploring mechanisms of apoptosis and the role of Bcl-2 family proteins in tumor survival. -
RIPK3 Inhibitor
GSK-872 hydrochloride is a potent inhibitor of receptor-interacting protein kinase 3 (RIPK3), exhibiting an IC50 of 1.8 nM for binding to the RIP3 kinase domain and an IC50 of 1.3 nM for inhibiting its kinase activity. This compound effectively reduces RIPK3-mediated necroptosis and inhibits the cytoplasmic translocation and expression of HMGB1. Additionally, GSK-872 hydrochloride has been shown to alleviate brain edema and neurological deficits in models of early brain injury, making it a valuable tool for studying necroptosis and related pathophysiological processes. -
RIPK1 Inhibitor
TP-030-1 is a potent inhibitor of receptor-interacting protein kinase 1 (RIPK1). It demonstrates a high affinity for human RIPK1 with a Ki value of 3.9 nM and an IC50 of 4.2 μM for mouse RIPK1. This compound is valuable for investigating the mechanisms underlying inflammatory and neurodegenerative diseases, providing insights into potential therapeutic interventions. -
RIPK2 Inhibitor
CSLP37 is a selective inhibitor of receptor-interacting protein kinase 2 (RIPK2), exhibiting an IC50 of 16.3 nM. This compound effectively suppresses cellular responses mediated by NOD1 and NOD2, while showing no significant inhibitory activity against RIPK1 and RIPK3. CSLP37 is a valuable tool for research into inflammatory signaling pathways and the role of RIPK2 in various diseases. -
RIPK1 Inhibitor
Cl-Necrostatin-1 is a selective inhibitor of receptor-interacting protein kinase 1 (RIPK1). It effectively blocks TNF-α-induced necroptosis in Jurkat cells lacking FADD, with an EC50 of 180 nM, thereby preventing caspase activation linked to death-domain receptor signaling. Additionally, Cl-Necrostatin-1 has been shown to decrease infarct size in a mouse model of middle cerebral artery occlusion (MCAO), making it a valuable tool for research in cardiovascular and cerebrovascular pathologies. -
RIPK1 Inhibitor
ZB-R-55 is a potent orally active inhibitor of receptor-interacting protein kinase 1 (RIPK1). This compound exhibits significant potential in modulating cell death pathways and inflammation, making it a valuable tool for researching sepsis and other inflammatory conditions. Its ability to selectively inhibit RIPK1 supports investigations into therapeutic strategies for diseases characterized by dysregulated necroptosis. -
RIPK3 Inhibitor
RIPK3-IN-3 is a selective inhibitor of the receptor-interacting protein kinase 3 (RIPK3), with an IC50 of 10 nM. This compound effectively prevents the phosphorylation of Mixed Lineage Kinase (MLKL), thereby inhibiting oligomerization of p-MLKL and subsequently blocking necroptosis. Additionally, RIPK3-IN-3 has been shown to downregulate CXCL5 secretion and suppress migration and invasion in AsPC-1 cancer cells, making it a valuable tool for studying necroptosis and related pathways in cancer research. -
RIPK1 Inhibitor
TP-030-2 is a potent RIPK1 inhibitor, with a human Ki of 0.43 nM and a mouse IC50 of 100 nM. This compound is designed for research applications targeting necroptosis and inflammatory pathways, making it a valuable tool for investigating cell death mechanisms and disease processes related to RIPK1 signaling. Its high specificity and efficacy support investigations into therapeutic strategies for conditions involving dysregulated cell death. -
RIPK1 Inhibitor
SZM679 is a selective inhibitor of receptor-interacting protein kinase 1 (RIPK1) with a Kd value of 8.6 nM, demonstrating high specificity over RIPK3 (>5000 nM). This compound effectively reverses tumor necrosis factor-induced systemic inflammatory responses and reduces Tau hyperphosphorylation and neuroinflammation in the hippocampus and cortex. SZM679 has significant potential for research applications in Alzheimer's disease and other neurodegenerative disorders. -
RIPK1 Inhibitor
Necrostatin-34 is a potent inhibitor of receptor-interacting protein kinase 1 (RIPK1). It stabilizes the inactive conformation of RIPK1 by binding to a specific pocket within the kinase domain, thereby preventing its activation. This compound is primarily utilized in research to explore necroptosis and cell death pathways, making it valuable for studies in inflammation, neurodegeneration, and cancer. -
RIPK1 Inhibitor
RI-962 is a potent and selective inhibitor of receptor-interacting protein kinase 1 (RIPK1), exhibiting an IC50 value of 35.0 nM. This compound is applicable in research focused on neurodegenerative disorders and inflammatory diseases, where modulation of RIPK1 activity can provide insights into disease mechanisms and potential therapeutic strategies. -
RIPK2/ALK2 Inhibitor
OD36 hydrochloride is a potent inhibitor of receptor-interacting protein kinase 2 (RIPK2) and an effective modulator of activin receptor-like kinase 2 (ALK2), exhibiting an IC50 of 5.3 nM against RIPK2. This macrocyclic compound demonstrates strong binding affinity for the ALK2 kinase ATP pocket, with a Kd of 37 nM. OD36 hydrochloride is suitable for research applications focused on signaling pathways involving RIPK2 and ALK2, relevant in studying various diseases, including inflammation and cancer. -
RIPK1 Inhibitor
AV123 is a potent RIPK1 inhibitor with an IC50 of 12.12 µM. This non-cytotoxic compound effectively blocks TNF-α-induced necroptosis, exhibiting an EC50 of 1.7 µM, while leaving apoptotic pathways unaffected. AV123 is valuable for investigating necrotic conditions, including ischemia-reperfusion injuries in the brain, heart, and kidney, as well as in various inflammatory and neurodegenerative diseases. -
RIPK1 Inhibitor
Oditrasertib is a selective reversible inhibitor of receptor-interacting protein kinase 1 (RIPK1), demonstrating oral bioavailability and the ability to penetrate the blood-brain barrier. It is primarily utilized in research related to chronic inflammatory diseases of the central nervous system, including amyotrophic lateral sclerosis and multiple sclerosis. Oditrasertib provides valuable insights into the mechanisms of RIPK1-mediated signaling pathways, aiding in the development of potential therapeutic strategies for these conditions. -
RIPK1 Inhibitor
Eclitasertib is a potent inhibitor of receptor-interacting protein kinase 1 (RIPK1), exhibiting an IC50 of 0.0375 µM. This compound is crucial for studying signaling pathways related to inflammation and cell death, making it valuable for research applications in apoptosis, neurodegeneration, and autoimmune diseases. Eclitasertib provides an effective tool for elucidating the role of RIPK1 in various biological contexts. -
RIPK3 Inhibitor
UH15-38 is a potent inhibitor of receptor-interacting protein kinase 3 (RIPK3), exhibiting an IC50 of 20 nM. This compound effectively blocks necroptosis activated by influenza A virus (IAV), reducing associated cellular damage. UH15-38 is valuable for research aimed at understanding viral pathogenesis and investigating potential therapeutic approaches for IAV-induced lung injury. -
RIPK3 Inhibitor
GSK840 is a highly potent inhibitor of receptor-interacting protein kinase 3 (RIPK3), exhibiting an IC50 of 0.9 nM for binding to the RIP3 kinase domain and an IC50 of 0.3 nM for inhibiting its kinase activity. This compound provides a valuable tool for studying RIPK3-mediated pathways and their role in programmed cell death and inflammation. GSK840 is applicable in research focused on neurodegenerative diseases, cancer, and immune responses. -
RIPK1/RIPK3 Inhibitor
RIPK1-IN-17 is a selective inhibitor of receptor-interacting protein kinase 1 (RIPK1) with a Kd of 17 nM, exhibiting minimal activity against RIPK3. This compound specifically targets necroptosis by inhibiting the phosphorylation of RIPK1, RIPK3, and MLKL, thereby preventing necroptotic cell death while allowing apoptosis to proceed. RIPK1-IN-17 has demonstrated protective effects in mice against hypothermia and mortality, making it a valuable tool for researching necroptosis-related conditions, particularly in the context of inflammatory response syndrome (SIRS). -
RIPK1 Inhibitor
Zharp1-211 is a selective inhibitor of RIPK1 kinase, with an EC50 of 53 nM and a Kd of 8.7 nM. This compound effectively reduces IFN-γ-induced STAT1 activation, presenting significant implications for the study of inflammatory responses. Zharp1-211 is suitable for research applications related to graft-versus-host disease and colon cancer, contributing to investigations into therapeutic strategies for these conditions. -
RIPK2 Inhibitor
Zharp2-1 is a potent inhibitor of receptor-interacting protein kinase 2 (RIPK2), which plays a critical role in inflammatory responses. This compound is particularly relevant in the context of inflammatory bowel disease (IBD), demonstrating the ability to modulate immune cell activation in response to muramyl dipeptide (MDP). Zharp2-1 effectively reduces MDP-induced small inguinal peritonitis and alleviates inflammation associated with DNBS-induced large inguinal conjunctivitis, making it a valuable tool for research in models of chronic inflammation and IBD. -
Caspase Inhibitor
Z-VA-DL-D-FMK is an irreversible caspase inhibitor that targets and binds to caspases, modulating their activity. This compound enhances the sensitivity of TNF-α, thereby influencing apoptotic pathways. Additionally, Z-VA-DL-D-FMK has been shown to activate HIV replication in infected T cells, such as ACH-2, making it valuable for studies in cell signaling and viral reactivation. -
Caspase-1 Inhibitor
Ac-AAVALLPAVLLALLAP-YVAD-CHO is a cell-permeable inhibitor of caspase-1, a key enzyme involved in inflammatory processes and programmed cell death. This compound demonstrates significant antitumor activity by modulating inflammatory responses and apoptosis. It is suitable for research applications focused on understanding caspase-1's role in cancer biology and related inflammatory diseases. -
Caspase Inhibitor
Ac-VEID-CHO is a potent peptide-derived caspase inhibitor that targets Caspase-3, Caspase-6, and Caspase-7, displaying IC50 values of 13.6 nM, 16.2 nM, and 162.1 nM, respectively. Additionally, it inhibits VEIDase activity with an IC50 of 0.49 µM. This compound is valuable for research into neurodegenerative diseases, including Alzheimer’s and Huntington’s disease, facilitating the study of apoptotic pathways and potential therapeutic interventions. -
Caspase-1 Inhibitor
Ac-Trp-Glu-His-Asp-Aldehyde is a selective inhibitor of caspase-1, demonstrating a remarkable Ki value of 56 pM. This compound plays a crucial role in the modulation of inflammatory processes by inhibiting the activation of caspase-1, an essential enzyme in the maturation of pro-inflammatory cytokines. It is widely utilized in research focused on innate immunity, inflammation, and therapeutic approaches for diseases driven by caspase-1 activity. -
Caspase Inhibitor
Ac-VAD-CMK is a pan-caspase inhibitor that effectively targets and inhibits various caspases, including caspases 1, 3, and 7. This compound is utilized in research to study apoptotic pathways and cell death mechanisms. Its application extends to investigating inflammation and neurodegenerative diseases where caspase activity is a critical factor. -
Caspase 4/5/9 Inhibitor
Ac-AAVALLPAVLLALLAP-LEHD-CHO is a potent inhibitor of caspases 4, 5, and 9. This compound demonstrates protective effects in MCF-7 cells treated with Neocarzinostatin, highlighting its potential applications in apoptosis research and cell survival studies. Its ability to modulate caspase activity makes it a valuable tool for investigating pathways related to cell death and disease mechanisms. -
Caspase-2/3 Inhibitor
Ac-VDVAD-CHO is a potent inhibitor of caspase-2 and caspase-3, with IC50 values of 46 nM and 15 nM, respectively. This compound effectively interferes with apoptotic signaling pathways, making it a valuable tool for research into cell death mechanisms. It is suitable for applications involving the study of apoptosis, neurodegeneration, and cancer. -
Caspase Inhibitor
Ac-VAD-CHO (Ac-Val-Ala-Asp-CHO) is a pan-caspase inhibitor that specifically targets and inhibits caspase activity. This compound effectively prevents the dissipation of mitochondrial membrane potential (MMP) and the release of cytochrome c in cells exposed to hypoxic conditions. Ac-VAD-CHO is widely used in research applications aimed at studying apoptosis and cell survival mechanisms. -
Caspase Inhibitor
Ac-LEHD-CHO is a selective inhibitor of caspase-8 and caspase-9. It effectively blocks apoptosis in hepatocytes and prevents hepatotoxicity induced by GalN/TNF-α. This compound is valuable for research applications involving cell death pathways and liver-related diseases. -
Caspase 3 Inhibitor, GSDME Inhibitor
Ac-DMLD-CMK is a potent inhibitor of caspase 3 and GSDME, functioning by binding directly to the catalytic domain of caspase-3. This compound effectively obstructs caspase-3-mediated cleavage of GSDME, thereby modulating the caspase 3-GSDME signaling pathway. Its primary biological activity includes the reduction of pyroptosis and apoptosis, as well as the suppression of inflammatory cytokines such as LDH, IL-6, IL-1β, and IL-18. Ac-DMLD-CMK shows potential in mitigating renal function decline, renal tubular epithelial cell damage, and chemotherapeutic nephrotoxicity. -
Caspase-1 Inhibitor
CZL80 is a potent caspase-1 inhibitor with an IC50 of 0.01 μM, capable of penetrating the blood-brain barrier. This compound is valuable for studying inflammatory pathways in neurological disorders, notably in the context of febrile seizures and their correlation with increased susceptibility to epilepsy. Research applications include investigating the role of caspase-1 in neuroinflammation and other brain-related pathologies. -
p53 Inhibitor
p-nitro-Pifithrin-α is a potent inhibitor of the p53 tumor suppressor protein. This cell-permeable compound effectively suppresses p53-mediated TGF-β1 expression in HK-2 kidney cells and prevents the activation of caspase-3 induced by Zika virus strains. Additionally, p-nitro-Pifithrin-α demonstrates protective effects against steatosis and liver injury in high-fat diet models, positioning it as a valuable tool in the study of non-alcoholic fatty liver disease and p53-related pathways. -
RIPK3 Inhibitor
RIPK3-IN-4 is a potent inhibitor of receptor-interacting protein kinase 3 (RIPK3), primarily known for its role in necroptosis and inflammation. This compound effectively protects HK-2 cells from damage, mitigating necroptosis and inflammatory responses. Additionally, RIPK3-IN-4 demonstrates significant protective effects against kidney damage induced by Cisplatin and ischemia/reperfusion, making it a valuable tool for research into acute kidney injury and related inflammatory conditions. -
RIPK3 Inhibitor
RIPK3-IN-6 is a type I inhibitor targeting Receptor-Interacting Serine/Threonine Kinase 3 (RIPK3), known for its role in programmed necrosis and inflammation. This compound exhibits poor selectivity across the RIPK family, particularly affecting the activity of RIPK2. It serves as a valuable tool for investigating necroptosis pathways and their implications in various diseases, providing insights into signaling processes and therapeutic targets. -
RIPK1 Inhibitor
SZM-1209 is a potent and specific inhibitor of RIPK1, demonstrating a Kd of 85 nM. It exhibits significant anti-necroptotic activity with an EC50 value of 22.4 ± 8.1 nM. SZM-1209 has been shown to mitigate conditions associated with systemic inflammatory response syndrome (SIRS) and acute lung injury (ALI), making it a valuable tool for research in inflammation-related pathologies. -
Caspase Like Protease Inhibitor
Ac-YVAD-FMK is a selective inhibitor of caspase 1-like proteases. It functions by covalently modifying the active site cysteine, thus blocking the enzymatic activity of these proteases. This compound is valuable in the study of inflammation and cell death pathways, particularly in research focused on the mechanisms of pyroptosis and other caspase-associated processes. -
Caspase Inhibitor
Z-LEED-FMK is a selective inhibitor of caspase-4 and caspase-13. This compound effectively inhibits the processing of caspase-1 in macrophages infected with S. typhimurium, making it a valuable tool for studying apoptosis and inflammatory pathways. Its specificity and inhibitory effects are significant for research applications in cell death mechanisms and inflammatory response investigations.
